Advertisement
UK markets close in 3 hours 57 minutes
  • FTSE 100

    8,154.48
    +33.24 (+0.41%)
     
  • FTSE 250

    19,954.20
    +27.61 (+0.14%)
     
  • AIM

    765.88
    +0.90 (+0.12%)
     
  • GBP/EUR

    1.1690
    +0.0006 (+0.06%)
     
  • GBP/USD

    1.2510
    -0.0014 (-0.11%)
     
  • Bitcoin GBP

    46,561.70
    +592.10 (+1.29%)
     
  • CMC Crypto 200

    1,258.53
    -12.21 (-0.96%)
     
  • S&P 500

    5,018.39
    -17.30 (-0.34%)
     
  • DOW

    37,903.29
    +87.37 (+0.23%)
     
  • CRUDE OIL

    79.43
    +0.43 (+0.54%)
     
  • GOLD FUTURES

    2,309.80
    -1.20 (-0.05%)
     
  • NIKKEI 225

    38,236.07
    -37.98 (-0.10%)
     
  • HANG SENG

    18,207.13
    +444.10 (+2.50%)
     
  • DAX

    17,959.24
    +27.07 (+0.15%)
     
  • CAC 40

    7,935.46
    -49.47 (-0.62%)
     

Incyte to Report First Quarter Financial Results

WILMINGTON, Del., April 11, 2024--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it has scheduled its first quarter financial results conference call and webcast for 8:00 a.m. ET on Tuesday, April 30, 2024.

The schedule for the press release and conference call/webcast is as follows:

Q1 2024 Press Release:

April 30, 2024 at 7:00 a.m. ET

Q1 2024 Conference Call:

April 30, 2024 at 8:00 a.m. ET

Domestic Dial-In Number:

877-407-3042

International Dial-In Number:

201-389-0864

Conference ID Number:

13745743

If you are unable to participate, a replay of the conference call will be available for thirty days. The replay dial-in number for the U.S. is 877-660-6853 and the dial-in number for international callers is 201-612-7415. To access the replay you will need the conference ID number 13745743.

ADVERTISEMENT

The live webcast with slides can be accessed at Investor.Incyte.com and will be available for replay for ninety days.

About Incyte

A global biopharmaceutical company on a mission to Solve On., Incyte follows the science to find solutions for patients with unmet medical needs. Through the discovery, development and commercialization of proprietary therapeutics, Incyte has established a portfolio of first-in-class medicines for patients and a strong pipeline of products in Oncology and Inflammation & Autoimmunity. Headquartered in Wilmington, Delaware, Incyte has operations in North America, Europe and Asia.

For additional information on Incyte, please visit Incyte.com or follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240411369652/en/

Contacts

Media
media@incyte.com

Investors
ir@incyte.com